1749P - Prevention of modifiable cancer risks in informal family caregivers of cancer patients: Implementation and evaluation of a personalised primary prevention intervention (PREV-AIDANT)

Background

The situation of caregiving can lead the informal family caregiver to neglect his or her own health, develop "risky” behaviours (smoking, alcohol consumption), adopt an unbalanced diet, encourage a sedentary lifestyle, and thus increase the risk of cancer. The sharing of the same lifestyle, including the same risk factors, within the informal family caregivers-patients dyad can also increase this risk. In addition, compared to the general population, informal family caregivers have a better perception of their risks and a greater motivation to change their behaviour. The objectives of the present study are to evaluate the feasibility and acceptability of a personalised primary prevention intervention for modifiable cancer risk factors in informal family caregivers of cancer patients.

Methods

The study is being conducted at the Léon Bérard Cancer Centre (Lyon, France), since April 2022, among informal family caregivers (first-degree relative or partner/spouse) who are adults and cancer-free. The personalised intervention was co-constructed with the representatives of informal family caregivers. It targets 6 risks factors (tobacco, alcohol, diet, physical activity, overweight/obesity, ultraviolet exposure) and screening. The intervention consists of an initial consultation (quantification of exposure, information on recommendations, drafting of a personalised primary prevention programme), support for the implementation and a four-month follow-up consultation (assessment of the actions taken, readjustment of the programme, exchanges to perpetuate the changes).

Results

To date, out of the 50 informal family caregivers expected, 26 have been seen at the initial consultation and 7 at the follow-up consultation. Inclusion will end in August 2023, the study looks feasible and acceptable, more results will be presented at the Congress.

Conclusions

The PREV-CARE transferability study of this intervention at the Institut Gustave Roussy (Paris, France) began in December 2022. Its objectives are to analyse the transferability of the intervention, to meet the challenges of territorial diversity, before considering evaluation on a larger scale.

Clinical trial identification

NCT05310045.

Editorial acknowledgement

Legal entity responsible for the study

Centre Léon Bérard.

Funding

Institut National du Cancer.

Disclosure

All authors have declared no conflicts of interest.